尊龙Z6官方网站

2 November, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 2256.HK) announced that its parent company, "Abbisko Cayman Limited" has changed its name to "Abbisko Medicine Co., Ltd". The name change officially took effect on 18 September, 2026, following the issuance of the Certificate of Incorporation on Change of Name by the Registrar of Companies in the Cayman Islands. The corresponding Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company was subsequently issued by the Hong Kong Companies Registry on 15 October, 2026.

Why the Change? The Reason Is Simple.

To make our name better reflect what we actually do.

The new name no longer includes a reference to the Company's place of incorporation and is now more closely aligned with "Abbisko Therapeutics", the name we have been using for many years. It more accurately reflects the Company's actual business operations and current stage of development, while reinforcing our vision and commitment to developing innovative medicines and addressing unmet medical needs.

What Matters to You Remains Unchanged？

• Stock Short Names | ABBISKO-B

• Stock Code | 2256

• Official Website | Remains unchanged

• Existing Share Certificates Bearing the Former Name | Remain valid as evidence of title to the shares and for trading, settlement, registration and delivery purposes. No exchange is required.

• New Share Certificates | Will only be issued under the Company's new name with effect from 9 November, 2026.

A new name, but the same commitment.

The change of company name will not affect any shareholder rights or the trading of the Company's shares on the Main Board of The Stock Exchange of Hong Kong Limited. Nor will it affect the Company's business operations or financial position.

For details, please refer to the full announcement: [CHANGE OF COMPANY NAME]